Melissa Watchorn
Psychiatric/Mental Health · South Sioux City, NENPI 1073249306
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.8% of the total across 205 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,681 and has fallen 69.8% since, to $508 in 2025.
Across 205 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$749
- Teva Pharmaceuticals USA, Inc.$603
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$500
- Vanda Pharmaceuticals Inc.$457
- AbbVie$414
- Otsuka America Pharmaceutical, Inc.$391
- plus $886 from 10 others
What the payments were for
- Food & beverage$3,74994%
- Education$2506%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 34 | $749 |
| Teva Pharmaceuticals USA, Inc. | 24 | $603 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 29 | $500 |
| Vanda Pharmaceuticals Inc. | 20 | $457 |
| AbbVie | 36 | $414 |
| Otsuka America Pharmaceutical, Inc. | 16 | $391 |
| Supernus Pharmaceuticals, Inc. | 6 | $248 |
| E.r. Squibb & Sons, L.L.C. | 4 | $156 |
| Corium, LLC | 16 | $150 |
| Neurocrine Biosciences, Inc. | 7 | $134 |
| Lundbeck LLC | 4 | $63 |
| Indivior Inc. | 3 | $39 |
| Johnson & Johnson | 2 | $33 |
| Amgen | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Novo Nordisk | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,999 in reported general payments places this provider in the 80th percentile of 255 psychiatric/mental health providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 49 | $157,983 |
| AristadaAripiprazole Lauroxil | 18 | $61,612 |
| CaplytaLumateperone Tosylate | 43 | $46,923 |
| VraylarCariprazine Hcl | 16 | $22,027 |
| RexultiBrexpiprazole | 17 | $19,716 |
| QuviviqDaridorexant Hcl | 13 | $6,480 |
| Aripiprazole | 67 | $5,337 |
| VyvanseLisdexamfetamine Dimesylate | 15 | $4,960 |
| Prazosin Hcl | 124 | $2,704 |
| Divalproex Sodium ErDivalproex Sodium | 52 | $2,212 |
| Duloxetine Hcl | 43 | $1,704 |
| Methylphenidate ErMethylphenidate Hcl | 14 | $1,697 |
| Quetiapine Fumarate | 115 | $1,553 |
| Buspirone Hcl | 86 | $1,275 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 64 | $1,252 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $33 | $157,98349 claims |
| Alkermes, Inc.Aristada | $749 | $61,61218 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $500 | $46,92343 claims |
| AbbVieVraylar | $414 | $22,02716 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $391 | $19,71617 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $16 | $4,96015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 255 psychiatric/mental health providers in Nebraska.
Other psychiatric/mental health in South Sioux City
- Dacia OakesonHastings$32K
- Margaret Emersonla Vista$30K
- Janelle HillOmaha$24K
- Kristi BoseOmaha$13K
- Robert LundholmOmaha$12K
- Sherry KropatschGrand Island$11K
- Virginia SmithOmaha$11K
- Christina HadleyOmaha$11K
- Suzanne GreggHastings$11K
- Helen TrotterLincoln$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.